ARROWHEAD PHARMACEUTICALS Reports 51.2% Decrease in Total Revenue for Third Quarter of FY 2023

August 11, 2023

🌥️Earnings Overview

For the third quarter of Fiscal Year 2023, ending June 30 2023, ARROWHEAD PHARMACEUTICALS ($NASDAQ:ARWR) reported total revenue of USD 15.8 million, a decrease of 51.2% from the same quarter in the prior year. Additionally, net income was reported as USD -103.0 million, a decline of -72.0 million year-on-year.


GoodWhale has conducted an analysis of ARROWHEAD PHARMACEUTICALS‘ financials and, according to the Star Chart, the company is strong in asset, growth, and profitability, but weak in dividend. Based on these results, ARROWHEAD PHARMACEUTICALS is classified as a ‘rhino’, meaning it has achieved moderate revenue or earnings growth. With its intermediate health score of 6/10 with regard to its cashflows and debt, this company may be an attractive option for investors who want to invest in companies that can weather a crisis without the risk of bankruptcy. Investors who are looking for consistent growth or high returns may not find what they are looking for in ARROWHEAD PHARMACEUTICALS, but those who want steady and reliable returns may find this company to be a good choice. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis
  • About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Arrowhead Pharmaceuticals. More…

    Total Revenues Net Income Net Margin
    256.21 -181.11 -70.7%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Arrowhead Pharmaceuticals. More…

    Operations Investing Financing
    -197.37 -90.22 253.76
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Arrowhead Pharmaceuticals. More…

    Total Assets Total Liabilities Book Value Per Share
    795.86 413.87 3.41
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Arrowhead Pharmaceuticals are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    27.5% -67.3%
    FCF Margin ROE ROA
    -133.8% -26.6% -13.5%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items

  • Peers

    It also has a large marketing and sales force that helps it to sell its products to customers.

    – Lin BioScience Inc ($TPEX:6696)

    Sangamo Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel genomic therapies. The Company’s technology platform is based on zinc finger DNA-binding proteins (ZFPs). The Company’s product candidates are designed to target and modulate the activity of specific genes associated with disease. The Company’s lead product candidates include SB-525, which is in Phase III clinical trials for the treatment of hemophilia A, and SB-913, which is in Phase I/II clinical trials for the treatment of Mucopolysaccharidosis Type I (MPS I).

    – Acer Therapeutics Inc ($NASDAQ:ACER)

    Acer Therapeutics Inc is a pharmaceutical company that focuses on the development and commercialization of therapies for serious rare and life-threatening diseases. The company’s lead product candidate, Etrasimod, is in clinical development for the treatment of ulcerative colitis, Crohn’s disease, and relapsing multiple sclerosis. Acer also has a portfolio of product candidates in various stages of development for the treatment of rare genetic disorders, including Duchenne muscular dystrophy, Friedreich’s ataxia, alpha-1 antitrypsin deficiency, and Gaucher disease.

    – Innovation1 Biotech Inc ($OTCPK:IVBT)

    Innovation1 Biotech Inc is a company that focuses on developing innovative treatments for diseases. The company has a market cap of 1.6M as of 2022 and a Return on Equity of -5.58%. The company’s market cap is the value of its outstanding shares of stock. The company’s ROE is a measure of how much profit it generates for shareholders.


    ARROWHEAD PHARMACEUTICALS reported their third quarter earnings results for the fiscal year 2023 with total revenue of USD 15.8 million, a decrease of 51.2% year-over-year. Net income reported was USD -103.0 million, a deterioration of -72.0 million from the same quarter last year. Investors should closely monitor ARROWHEAD PHARMACEUTICALS as it continues its financial recovery and business development. The company’s current financial performance and future outlook will be key factors to consider when making an investment decision.

    However, investors should also keep an eye on the competitive landscape for pharmaceuticals products in order to identify any possible areas of growth and opportunity for ARROWHEAD PHARMACEUTICALS.

    Recent Posts

    Leave a Comment